These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9397340)

  • 1. Modeling medical trials in pharmacoeconomics using a temporal object model.
    Goralwalla IA; Ozsu MT; Szafron D
    Comput Biol Med; 1997 Sep; 27(5):369-87. PubMed ID: 9397340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of paper-based and electronic data collection process in clinical trials: costs simulation study.
    Pavlović I; Kern T; Miklavcic D
    Contemp Clin Trials; 2009 Jul; 30(4):300-16. PubMed ID: 19345286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomic series: Part I. Pharmacoeconomics and the evaluation of drugs and services.
    McGhan WF
    Hosp Formul; 1993 Apr; 28(4):365-6, 371-3, 377-8. PubMed ID: 10125323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacoeconomics of acne treatment: where are we heading?
    Inglese MJ; Fleischer AB; Feldman SR; Balkrishnan R
    J Dermatolog Treat; 2008; 19(1):27-37. PubMed ID: 18273722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guidelines for performing a pharmacoeconomic analysis.
    Jolicoeur LM; Jones-Grizzle AJ; Boyer JG
    Am J Hosp Pharm; 1992 Jul; 49(7):1741-7. PubMed ID: 1621734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomics: determining the value of drug therapy.
    Peterson C
    Healthplan; 1998; 39(3):44-50. PubMed ID: 10181751
    [No Abstract]   [Full Text] [Related]  

  • 8. Protocol-driven costs in trial-based pharmacoeconomic analyses.
    Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):673-5. PubMed ID: 22098282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linked Pharmacometric-Pharmacoeconomic Modeling and Simulation in Clinical Drug Development.
    Hill-McManus D; Marshall S; Liu J; Willke RJ; Hughes DA
    Clin Pharmacol Ther; 2021 Jul; 110(1):49-63. PubMed ID: 32936931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacoeconomics of high-cost biotechnology products.
    Dana WJ; Farthing K
    Pharm Pract Manag Q; 1998 Jul; 18(2):23-31. PubMed ID: 10185236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluations during early (phase II) drug development: a role for clinical trial simulations?
    Hughes DA; Walley T
    Pharmacoeconomics; 2001; 19(11):1069-77. PubMed ID: 11735674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence of pharmacoeconomic studies to national guidelines in the Netherlands.
    Atthobari J; Bos JM; Boersma C; Brouwers JR; de Jong-van den Berg LT; Postma MJ
    Pharm World Sci; 2005 Oct; 27(5):364-70. PubMed ID: 16341742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Providing cost-effective therapy using pharmacoeconomic evaluations: the public sector approach.
    Finder S
    Clin Ther; 1997; 19(1):160-6. PubMed ID: 9182021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of therapeutic drug monitoring in pharmacoeconomics.
    Destache CJ
    Ther Drug Monit; 1993 Dec; 15(6):608-10. PubMed ID: 8122303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The difference in mean costs as a pharmacoeconomic outcome variable: power considerations.
    Bouckaert A; Crott R
    Control Clin Trials; 1997 Feb; 18(1):58-64. PubMed ID: 9055053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of pharmacoeconomics and pharmaceutical outcomes evaluations.
    Reeder CE
    Am J Health Syst Pharm; 1995 Oct; 52(19 Suppl 4):S5-8. PubMed ID: 8846244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomic component of a clinical trial conducted in Latin America. Conceptual and empirical considerations.
    Reinharz D; Saldaña VR; Follador W; Asche C
    Int J Technol Assess Health Care; 2001; 17(4):571-8. PubMed ID: 11758300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Artificial neural network in pharmacoeconomics.
    Polak S; Skowron A; Mendyk A; Brandys J
    Stud Health Technol Inform; 2004; 105():241-9. PubMed ID: 15718613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.